Compare Results of Mitral Valve Replacement or Repair in the Surgical Treatment of Obstructive Hypertrophic Cardiomyopathy With Severe Mitral Insufficiency.

Meshalkin Research Institute of Pathology of Circulation1 site in 1 country82 target enrollmentOctober 2013

ConditionsHypertrophic Obstructive Cardiomyopathy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hypertrophic Obstructive Cardiomyopathy
Sponsor: Meshalkin Research Institute of Pathology of Circulation
Enrollment: 82
Locations: 1
Primary Endpoint: The function of the mitral valve (mitral regurgitation return, prosthesis dysfunction)
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Compare the results of reconstruction and mitral valve replacement in the surgical treatment of obstructive hypertrophic cardiomyopathy with severe mitral insufficiency.

Detailed Description

Many years myoectomy for Morrow was the gold standard in the treatment of obstructive hypertrophic cardiomyopathy. Currently more retrospective data in the literature about the good results the extended septal myectomy. But the question remains what is best for patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency: use extended myoectomy with mitral valve repair a or replacement.

Registry

clinicaltrials.gov

Start Date

October 2013

End Date

May 2015

Last Updated

10 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Meshalkin Research Institute of Pathology of Circulation

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Able to sign Informed Consent and Release of Medical Information forms
•Age ≥ 18 years
•obstructive hypertrophic cardiomyopathy
•surgically significant mitral insufficiency
•II-IV (NYHA),
•average systolic pressure gradient greater than 50 mm Hg. Art. at rest;
•basal or medium ventricular obstruction

Exclusion Criteria

•Related defect of the aortic valve;
•Organic mitral valve disease (dysplasia, rheumatic fever, infective endocarditis);
•Surgically significant coronary artery lesions;
•Patients requiring implantation of a cardioverter-defibrillator